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ABSTRACT The meperidine analogue derivative
l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in-
duces nigrostriatal fiber damage and severe parkinsonism in
humans and animals. MPTP-induced parkinsonism has been
proposed as a model ofParkinson disease, but doubts have been
raised about whether the patterns of nigrostriatal fiber loss in
the two conditions are similar. We report here observations on
[3H]mazindol monoamine (principally dopamine) uptake-site
binding in the striatum of monkeys (Saimiri sciureus) exposed
to low doses of MPTP. We show that this treatment can
produce a pattern of nigrostriatal degeneration characteristic
of that seen in Parkinson disease, in which there is greater
depletion of dopaminergic markers in the putamen than in the
caudate nucleus, especially posteriorly. Moreover, within the
regions of diminished uptake-site binding in the MPTP-treated
monkeys, there is differential preservation of binding in stri-
osomes relative to the surrounding matrix. We suggest that
both regional and striosome/matrix patterns of nigrostriatal
depletion are key features of MPTP-induced neurodegenera-
tion and that both patterns may provide dues to the mecha-
nisms underlying neurodegeneration in Parkinson disease as
well.
Exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) induces a behavioral state in humans and other
primates that strongly resembles idiopathic Parkinson dis-
ease (1, 2). MPTP-induced parkinsonism is highly responsive
to L-dopa therapy, and in the brains of MPTP-treated pri-
mates (including one human) it has been shown that there is
a concomitant loss of dopamine-containing neurons of the
nigrostriatal tract, also a hallmark of pathology in Parkinson
disease (3-8). These characteristics suggest that MPTP-
induced parkinsonism may be similar to the idiopathic dis-
ease and have motivated a large body of work aimed at
understanding the molecular mechanisms underlying MPTP-
induced neurotoxicity (8-11).
A key feature of the neurodegeneration in Parkinson dis-
ease is a characteristic gradient of dopamine loss in the
striatum, with greater defects in the putamen than in the
caudate nucleus and greater defects posteriorly than anteri-
orly in the putamen (4-7, 12). This pattern has not been found
consistently in MPTP-treated monkeys (13-16). Instead,
MPTP is capable of depleting dopaminergic markers from
nearly the entire caudate nucleus as well as from the puta-
men, leaving only the ventral striatum (nucleus accumbens
and olfactory tubercle) and the adjoining ventral caudoputa-
men relatively spared. This more global deficit has been
interpreted as suggesting that MPTP-induced parkinsonism,
for all its similarities to Parkinson disease, may not be a
suitable model for the disease (14, 15, 17). This is a funda-
mentally important issue, because the MPTP model not only
implicates environmental toxins as possible etiologic factors
in Parkinson disease (11) but also, if correct, could greatly
enhance efforts to understand the molecular basis of cell
death in Parkinson disease (18).
To address this issue experimentally, we treated monkeys
with low doses of MPTP in an attempt to bring about inter-
mediate levels of nigrostriatal fiber loss. We monitored mono-
amine uptake-site binding with [3H]mazindol as a postmortem
marker for monoaminergic terminals (19). We looked for
gradients of reduced [3H]mazindol binding, and we also used
the binding distributions to determine whether dopamine-
containing fibers innervating the two main neurochemical
compartments of the primate striatum, the striosomes and
matrix (20, 21), were differently affected as suggested for
MPTP intoxication in dogs (22, 23).
METHODS
MPTP Treatment and Behavioral Observations. Six adult
feral squirrel monkeys (Saimiri sciureus) were given single
subcutaneous injections of MPTP at the following doses: 1.5
mg/kg (Sql3 and Sql4), 2 mg/kg (Sqil and Sql2), and 2.5
mg/kg (Sq7 and Sq8) (see Table 1). The behavior of each
animal was observed, and total body movements were mea-
sured in 1-hr sessions with a photocell activity monitor
capable of sensing body movements with an amplitude
greater than one body width. Four to 29 sessions were given
prior to administration of MPTP, and 5-10 afterwards (see
Table 1).
Tissue Preparation. Ten days after the treatment, these
animals and three untreated control squirrel monkeys were
deeply anesthetized with sodium pentobarbital (12 mg/kg),
and their brains were removed, quickly cut into blocks, and
frozen in powdered dry ice. Serial transverse sections 10-15
Am thick were cut on a cryostat, thaw-mounted onto gelatin-
coated slides, air dried, and stored in 20 sets of regularly
spaced sections at -20'C until use.
[3H]Mazindol Binding. Binding incubations were per-
formed as described previously (19, 24) on two complete sets
of sections for each brain and on additional control and trial
sections. Frozen sections were brought to room temperature,
were preincubated for 5 min at 40C in 50 mM Tris-HCl buffer,
pH 7.9, containing 120 mM NaCl and 5 mM KCI to wash off
endogenous ligand, and were incubated for 40 min with 15 nM
[3H]mazindol (22.7 Ci/mmol; Du Pont NEN; 1 Ci = 37 GBq)
in 50 mM Tris HCl buffer containing 300 mM NaCl, 5 mM
Abbreviation: MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyri-
dine.
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KCI, and 0.3 AM desimipramine to block the'norepinephrine
transporter. After incubation, the sections were washed in
the incubation buffer (two times for 3 min) and ice-cold water
(10 sec) and dried under a cool air stream. Nonspecific
binding was determined for control sections incubated in the
presence of 30 ,uM benztropine. The standard sets of sections
were apposed to 3H-sensitive film (LKB Ultrofilm) for 2
weeks; films with trial sections were exposed for shorter and
longer times. Tritium standards (3H Micro-scales, Amer-
sham) and nonspecific binding control sections were apposed
to each film. To permit within-case analysis, films with
sections at different anteroposterior levels from each control
and each MPTP-treated monkey were prepared. To permit
cross-case analysis, sets of sections from different MPTP-
treated monkeys were applied to the same films (along with
control sections and sections from control monkeys). Sec-
tions and films were treated as nearly identically as possible.
Densitometry. Densitometric analysis was performed with
a Biocom 200 Image Analyzer (Les Ulis, France). For
analysis ofbinding levels in the striatal matrix, optical density
measurements were made at 12 sites per section, avoiding
striosomes where these could be identified as such. For each
monkey, measurements were made in five sections (10 hemi-
spheres) per rostrocaudal level (rostral, middle, and caudal,
see Fig. 3A), with occasional exceptions where tissue was
missing. Optical density values were converted to nCi/mg
tissue equivalent with the aid of autoradiographic standards
on the films. Values for right and left sides were pooled.
FIG. 1. [3H]Mazindol binding autoradiograms illustrating patterns of partial depletion of monoamine uptake sites in the squirrel monkey
striatum induced by low-dose MPTP treatment (A, B, C) relative to control levels of binding in an untreated squirrel monkey (A', B', C'). Binding
appears white. Sections inA-C show anterior, middle, and posterior striatal levels from Sqil (2.0 mg ofMPTP per kg, 10-day survival). Sections
in A'-C' show approximately matched levels from control SqlO. Sections were processed as similarly as possible; those shown in A, B, and
C were incubated together and were exposed on the same films; sections in A', B', and C' were incubated together; all films were exposed for
15 days. Note in B and C that the greatest loss of binding in the MPTP-treated monkey occurs posteriorly and laterally, but that patches of spared
binding (examples at asterisks) occur in regions of otherwise diminished binding. Loss of binding in the anterior striatum (A) is smaller, but
patterns of heightened binding nevertheless are visible in a background of slightly reduced binding. Patches of reduced binding appear in the
medial and ventral caudate nucleus in both the control and MPTP-treated monkeys (examples at arrowheads). CN, caudate nucleus; P. putamen;
IC, internal capsule; NA, nucleus accumbens. (Scale bar indicates 1 mm.)
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Drawings at the top of Fig. 3 show schematically the 12 sites
sampled in representative rostral, middle, and caudal sec-
tions. The tail of the caudate nucleus was not analyzed.
Additional densitometric measurements of patches of height-
ened binding visible in the striatum were also made and were
analyzed separately. Values from three control monkeys
(Sq4, -6, and -10) were pooled, but values from different
MPTP-treated monkeys were not pooled because the front of
diminished binding observed (see below) reached different
levels in different monkeys.
RESULTS
Two striking patterns of partial loss of [3H]mazindol binding
occurred in the caudate-putamen of the MPTP-treated mon-
keys (Fig. 1). The first was a systematic topography of
diminished binding in which the putamen was more affected
than the caudate nucleus, and posterior striatal levels were
more affected than anterior levels. These lateral-to-medial
and posterior-to-anterior gradients are illustrated in Fig. 1 for
Sqil, which received MPTP at 2.0 mg/kg. Binding in the
ventral caudate nucleus and putamen was least affected at all
levels. In the control monkeys, marked gradients in binding
were not observed in the caudate nucleus and putamen, but
binding in the ventral striatum was lower than that in the
dorsal striatum.
The second pattern of binding found in the MPTP-treated
brains was a relative sparing of [3H]mazindol signal in strio-
somes. As shown in Fig. 1, in the striatal regions exhibiting
decreases in binding, there were scattered focal zones in which
much higher binding was present. These patches ofheightened
binding lined up with striosomes identified in adjacent sections
stained for butyrylcholinesterase activity (Fig. 2). In ventral
districts, where considerable [3H]mazindol binding persisted,
striosomes could often be recognized as zones of reduced
labeling in the MPTP-treated monkeys, as they can be in
control monkeys (Fig. 1 and refs. 24 and 26).
To make quantitative estimates of the reduced binding
found after MPTP treatment, we carried out densitometry on
films from all animals. Fig. 3 summarizes the values for Sqil,
based on samplings of the matrix compartment in relation to
mean values for the control monkeys, also from samples
taken from extrastriosomal matrix insofar as it could be
identified. The quantitative data demonstrate relative sparing
of [3H]mazindol binding in the most medial, ventral, and
rostral parts of the striatum, and they show that the gradients
of loss of binding were systematic. Densitometry on the
patches of relatively spared [3H]mazindol binding suggested
that binding in striosomes reached a maximum of 100%o
enhancement relative to adjoining matrix in the caudate
nucleus and a maximum of 160% enhancement relative to
matrix in the putamen.
There were marked individual differences in the extent of
the reduced [3H]mazindol binding found in the striatum of the
six MPTP-treated monkeys. In one monkey (Sq8, given
2.5 mg/kg), there was nearly total depletion of [3H]mazindol
binding in the caudate-putamen, even rostrally. This pattern
resembled the patterns reported for experiments in which large
or repeated doses of MPTP were given (13-16). In a second
monkey (Sql4, given 1.5 mg/kg), the MPTP treatment was
nearly ineffective in reducing [3H]mazindol binding sites ex-
cept in the posterior putamen. In the four remaining animals,
caudolateral-to-rostroniedial gradients of diminished binding
were prominent, and patches ofrelatively preserved binding in
striosomes appeared in the regions of partial loss in all but the
most severely affected ofthese four monkeys (Sql3, given 1.5
mg/kg). In this monkey, binding was reduced nearly to back-
ground levels except far anteriorly, and even there binding in
both striosomes and matrix was reduced relative to that in the
controls. The forward and medial progression of the loss of
binding varied from monkey to monkey, as did the relative
degree of reduced binding in the dorsal third of the putamen
(very marked in Sq8, Sql2, and Sql3; less marked in Sq7 and
Sqil). The prominence of striosomal sparing also varied
(especially marked in Sq7 and Sqil, less pronounced in
others). Despite such individual differences, the general to-
pographic and compartmental patterns of loss in the monkeys
were remarkably consistent.
The relation between the dose of MPTP administered and
the severity of loss of [3H]mazindol binding was not clear,
because the next-to-most severe and the least severe deple-
tions occurred in monkeys given the same dose of MPTP
(Sql3 and Sql4, respectively, 1.5 mg/kg). The behavioral
measurements (Table 1) showed marked loss of total body
movements in all monkeys, with remaining activity of2-29%.
All monkeys also showed marked bradykinesia. Of the two
monkeys showing the smallest diminished total body move-
ments relative to controls, one (Sql4) had the least affected
[3H]mazindol binding. The second (Sqil) showed interme-
diate loss but considerable sparing of binding in the putame-
nal matrix except in an oblique central band (Fig. 1).
DISCUSSION
These findings demonstrate that MPITP-induced loss of mono-
amine uptake-site binding in the primate caudate nucleus and
FIG. 2. Photographs of two serial
sections demonstrating that patches of
spared [3H]mazindol binding in the
MPTP-treated squirrel monkey stria-
tum (A) correspond to striosomes iden-
tified by butyrylthiocholinesterase his-
tochemistry (B). A shows five promi-
nent patches of binding (asterisks) in
the putamen of Sqil. Corresponding
zones in B appear as sites with butyryl-
cholinesterase-rich rims (see asterisks),
which mark striosomes in this part of
the striatum (25). (Scale bar indicates 1
mm.)
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FIG. 3. Summary of densitometric measurements of[3H]mazindol
binding in the striatal matrix in MPTP-treated monkey Sqil (see Figs.
1 and 2) in relation to mean values for control monkeys Sq4, Sq6, and
SqlO (see Fig. 1 for SqlO). Black bars: values for MPTP-treated
monkey (including SEMs). White bars: mean values and SEMs for
controls. The drawings at the top show in diagrammatic form the 12
sites sampled at rostral, middle, and caudal levels of the striatum. The
values for each of the 12 sites are plotted in the histograms separately
for rostral (R), middle (M), and caudal (C) levels. Values for the dorsal
(1, 4, 7, 10), intermediate (2, 5, 8, 11), and ventral (3, 6, 9, 12) sites are
plotted in separate histograms. The medial to lateral dimension at each
height is displayed from left (most medial) to right (most lateral).
putamen can present a lateral-to-medial gradient strikingly
similar to that reported for Parkinson disease, with relative
sparing of nigrostriatal markers in the caudate nucleus (4-6).
Further, the posterior putamen showed particular vulnerabil-
ity, as found also in Parkinson disease. [3HjMazindol binding
is a reliable marker for monoamine uptake sites, but it is only
an indirect marker for fibers bearing binding sites. Decreases
(or increases) in binding relative to control values could reflect
differential regulation of monoamine transporters. Neverthe-
less, the most likely interpretation of our findings is that the
marked decreases represent degenerative changes.
Our observations thus suggest that in MPTP-induced par-
kinsonism in some monkeys, as in Parkinson disease in some
humans, there is primary putamenal dopamine loss during the
progression of the disease. The fact that the loss of[3H]mazin-
dol binding ranged from near total depletion in one monkey to
only slight posterior putamenal depletion in another further
suggests that the patterns of partial loss in the other four
monkeys represented intermediate phases preceding complete
destruction of nigrostriatal terminals. This point is particularly
important when comparing the MPTP-induced changes to
those in Parkinson disease, as dopaminergic cell loss in the
idiopathic disease is also nearly always partial (3, 28, 29).
Although the predominance of putamenal loss of
[3H]mazindol binding we saw in the MPTP monkeys is similar
to the predominant putamenal loss of dopamine described for
Parkinson disease brains (4-7, 12), we did not see a reverse
(rostral most, caudal least) gradient of depletion in the
caudate nucleus, as reported for Parkinson disease brains by
some groups (4, 12). The lateral-to-medial gradient of uptake-
site loss we found in the striatum does parallel findings for
Parkinson disease (6). The fields of diminished [3H]mazindol
binding in the putamen and lateral caudate nucleus seemed
related, as did the relative striosome/matrix binding in the
two nuclei: often patches of strong binding in striosomes
appeared just on either side of the internal capsule.
There was remarkably clear evidence for relative preser-
vation of uptake-site binding in striosomes located in other-
wise clearly affected striatal regions in these MPTP-treated
monkeys. In some severely-depleted regions, most of the
remaining binding was in striosomes. This pattern suggests
that the striosomes, like the medial caudate nucleus and
anterior putamen, are differently, and perhaps less rapidly,
affected than the matrix and remaining parts of the putamen
and caudate nucleus. Ultimately, however, binding in the
striosomes can also be depleted, as shown in our own most
severely affected monkeys and by findings in other studies
(13, 14). The differences in loss of binding between strio-
somes and matrix thus do not seem to reflect differences in
ultimate susceptibility of the two striatal compartments but,
rather, differences in the rate of onset or progression of the
MPTP-induced pathology.
It is not known whether such a differential striosome-
matrix pattern of vulnerability occurs in the striatum in
Parkinson disease. A compartmental pattern of nigrostriatal
damage has been reported for MPTP-treated dogs, in which
marked fiber degeneration was seen in the matrix but not in
striosomes at 8- to 14-day survival times (22, 23). Further-
more, after chronic MPTP treatment and extended (15-week)
survival times, differential up-regulation of g opiate receptor
ligand binding has been found in the striosomal system in
monkeys (27). Clearly, a key feature to look for in early-stage
neuropathology in Parkinson disease will be differential vul-
nerability of the striosome and matrix compartments.
The pronounced neurochemical gradients and compart-
mentalization in the striatum (21, 28), or the corresponding
nonuniform neurochemistry of the midbrain dopaminergic
cell groups (18, 28, 29), or both could contribute to the
patterns of differential vulnerability reported here. For ex-
ample, it has been proposed that differences in monoamine
uptake-site concentration in different regions of the normal
striatum could result in lower rates of uptake of the toxic
metabolites of MPTP or MPTP-like substances in some
regions (such as ventral striatum) than in others and, conse-
quently, lower relative rates of nigrostriatal terminal damage
(24, 30). Our findings confirm relatively low levels of uptake-
site binding in the ventral striatum of normal monkeys and
show a relative sparing of uptake-site binding in the ventral
striatum of MPTP-treated monkeys. However, the topogra-
phy of binding in the MPTP-treated monkeys did not support
such an inverse correlation for the dorsal striatum. First, we
did not observe pronounced gradients of binding in the
controls that would predict the particular vulnerability of the
posterior putamen (Fig. 2). Second, the most dramatic in-
stances of striosomal preservation of binding were in the
putamen and lateral caudate nucleus of the MPTP-treated
monkeys, particularly caudally, whereas the relatively re-
Proc. Natl. Acad. Sci. USA 89 (1992)
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Table 1. Motor activity before and after MPTP treatment
Body movements per min
MPTP dose, (number of sessions) % of pretreatment
Monkey mg/kg Before treatment After treatment activity after MPTP
Sql3 1.5 28.82 ± 2.87 (21) 2.67 ± 0.36 (10) 9.25
Sql4 1.5 24.81 ± 2.95 (27) 6.14 ± 1.11 (10) 26.2
Sq1l 2.0 15.38 ± 0.87 (29) 4.47 ± 1.26 (10) 29.1
Sql2 2.0 26.92 ± 2.77 (21) 2.98 ± 0.76 (10) 11.0
Sq7 2.5 46.99 ± 3.21 (4) 1.19 ± 0.27 (5) 2.5
Sq8 2.5 34.53 ± 3.98 (5) 0.69 ± 0.44 (5) 1.9
Body movements are reported as mean ± SEM.
duced [3H]mazindol binding in striosomes of the normal
primate striatum tends to occur medially and anteriorly (24,
26). In fact, in one of our control monkeys (SqlO), dorsolat-
eral striosomes even appeared as regions of slightly (4-10%)
elevated binding (Fig. 1).
The variations in individual susceptibility seen in this study
have implications for the hypothesis that an environmental
agent, possibly a toxin, could precipitate Parkinson disease. We
found that single subcutaneous injections ofMPTP at the same
or similar doses can produce a range of neurodegenerative
effects from nearly complete to very mild loss of [3H]mazindol
binding. We also noted individual differences in the severity of
behavioral symptoms shown by the monkeys. Such differences
are also characteristics of primates treated with MPTP for
prolonged periods (16, 31, 32), and they are reminiscent of the
variability in symptoms and neurodegeneration in Parkinson
disease. We did not determine the origins ofsuch variability, but
our findings may have direct bearing on the complexity of
epidemiological data on the incidence of parkinsonian disor-
ders. One potentially important variable, age, was unknown for
the feral monkeys we used.
Our findings clearly raise the possibility that low-dose
exposure to neurotoxins in humans might produce a gradual
loss of dopaminergic nigrostriatal fibers following the gradi-
ents and compartmental patterns we describe here. The
preferential early loss of nigrostriatal markers in the striatal
matrix, especially in the sensorimotor part of the putamen
and lateral caudate nucleus, is consistent with early motor
symptoms of MPTP-induced parkinsonism, also a feature of
Parkinson disease. Nearly all of the major projections to the
primate striatum that originate in somatic sensory and motor
cortex terminate in the putamen and adjoining lateral margin
of the caudate nucleus (33, 34). The low-dose MPTP-treated
monkey may provide a new model for studying the differen-
tial vulnerability of the putamen and the extrastriosomal
matrix with respect to their dopaminergic innervations and
the functional effects of this vulnerability. The pattern of loss
we found further suggests that functions of the basal ganglia
relying on nigrostriatal modulation would increasingly in-
volve the medial caudate nucleus and the striosomal system
in neurotoxin-induced parkinsonism. These striatal subdivi-
sions receive incoming information from parts of the pre-
frontal association cortex, but they do not receive a major
sensorimotor cortical input (refs. 35-37; F. M. Eblen and
A.M.G., unpublished observations). Such an imbalance be-
tween dopamine-denervated sensorimotor striatum and do-
pamine-innervated frontolimbic-associated striatum could
help to account for some of the selective behavioral deficits
that occur during the evolution of parkinsonian syndromes.
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